Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 2
1999 1
2003 1
2004 7
2005 3
2006 6
2007 7
2008 5
2009 8
2010 6
2011 5
2012 4
2013 3
2014 10
2015 7
2016 5
2017 5
2018 3
2019 3
2020 3
2021 3
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J. Shomali W, et al. Am J Hematol. 2022 Jan 1;97(1):129-148. doi: 10.1002/ajh.26352. Epub 2021 Oct 8. Am J Hematol. 2022. PMID: 34533850 Free article.
This includes the major category "myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2", and the myeloproliferative neoplasm subtype, "chronic eosinophilic leukemia, not otherwise specified" (CEL, NOS). …
This includes the major category "myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JA …
Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.
Requena G, van den Bosch J, Akuthota P, Kovalszki A, Steinfeld J, Kwon N, Van Dyke MK. Requena G, et al. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2125-2134. doi: 10.1016/j.jaip.2022.03.034. Epub 2022 Apr 22. J Allergy Clin Immunol Pract. 2022. PMID: 35470096 Free article. Review.
OBJECTIVE: To describe disease characteristics, treatment, and outcomes of patients with idiopathic (I-HES), myeloproliferative (M-HES), lymphocytic (L-HES), and chronic eosinophilic leukemia, not otherwise specified (CEL-NOS) among HES case reports and aggre …
OBJECTIVE: To describe disease characteristics, treatment, and outcomes of patients with idiopathic (I-HES), myeloproliferative (M-HES), lym …
World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J. Shomali W, et al. Am J Hematol. 2019 Oct;94(10):1149-1167. doi: 10.1002/ajh.25617. Am J Hematol. 2019. PMID: 31423623 Free article. Review.
This includes the major category "myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2", and the MPN subtype, "chronic eosinophilic leukemia, not otherwise specified" (CEL, NOS). ...
This includes the major category "myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JA …
Jak-2 positive myeloproliferative neoplasms.
Muxí PJ, Oliver AC. Muxí PJ, et al. Curr Treat Options Oncol. 2014 Jun;15(2):147-56. doi: 10.1007/s11864-014-0279-3. Curr Treat Options Oncol. 2014. PMID: 24627006 Review.
The term includes a range of conditions, [ie, BCR-ABL-positive chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), primary myelofibrosis (PMF), essential thromobocythemia (ET), chronic eosinophilic leukemia not oth …
The term includes a range of conditions, [ie, BCR-ABL-positive chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), poly …
Myeloid neoplasms with eosinophilia.
Reiter A, Gotlib J. Reiter A, et al. Blood. 2017 Feb 9;129(6):704-714. doi: 10.1182/blood-2016-10-695973. Epub 2016 Dec 27. Blood. 2017. PMID: 28028030 Free article. Review.
Similar poor prognosis outcomes may be observed with rearrangements of FLT3 or ABL1 (eg, both of which commonly partner with ETV6), and further investigation is needed to validate their inclusion in the current WHO-defined group of eosinophilia-associated TK fusion-driven neoplas …
Similar poor prognosis outcomes may be observed with rearrangements of FLT3 or ABL1 (eg, both of which commonly partner with ETV6), and furt …
S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.
Lee JS, Lee NR, Kashif A, Yang SJ, Nam AR, Song IC, Gong SJ, Hong MH, Kim G, Seok PR, Lee MS, Sung KH, Kim IS. Lee JS, et al. Front Immunol. 2020 Aug 6;11:1258. doi: 10.3389/fimmu.2020.01258. eCollection 2020. Front Immunol. 2020. PMID: 32903598 Free PMC article.
S100A8 and S100A9 function as essential factors in inflammation and also exert antitumor or tumorigenic activity depending on the type of cancer. Chronic eosinophilic leukemia (CEL) is a rare hematological malignancy having elevated levels of eosinophils and …
S100A8 and S100A9 function as essential factors in inflammation and also exert antitumor or tumorigenic activity depending on the type of ca …
Eosinophilia in Hematologic Disorders.
Falchi L, Verstovsek S. Falchi L, et al. Immunol Allergy Clin North Am. 2015 Aug;35(3):439-52. doi: 10.1016/j.iac.2015.04.004. Immunol Allergy Clin North Am. 2015. PMID: 26209894 Free PMC article. Review.
There are 3 main types of eosinophilia-associated myeloid neoplasms (MN-eos): myeloid and lymphoid neoplasms, chronic eosinophilic leukemia not otherwise specified, and idiopathic hypereosinophilic syndrome (HES). ...
There are 3 main types of eosinophilia-associated myeloid neoplasms (MN-eos): myeloid and lymphoid neoplasms, chronic eosinophilic …
Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
Lierman E, Cools J. Lierman E, et al. Expert Rev Anticancer Ther. 2009 Sep;9(9):1295-304. doi: 10.1586/era.09.82. Expert Rev Anticancer Ther. 2009. PMID: 19761433 Review.
In cases for which clonality is clear, but no PDGFRA, PDGFRB or FGFR1 rearrangement could be demonstrated, the term 'chronic eosinophilic leukemia, not otherwise specified' is preferred. ...Additional potent kinase inhibitors have been identified, also includ …
In cases for which clonality is clear, but no PDGFRA, PDGFRB or FGFR1 rearrangement could be demonstrated, the term 'chronic eosin …
Eosinophilia in mast cell disease.
Kovalszki A, Weller PF. Kovalszki A, et al. Immunol Allergy Clin North Am. 2014 May;34(2):357-64. doi: 10.1016/j.iac.2014.01.013. Epub 2014 Mar 13. Immunol Allergy Clin North Am. 2014. PMID: 24745679 Free PMC article. Review.
Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
Yamada Y, Cancelas JA, Rothenberg ME. Yamada Y, et al. Int Arch Allergy Immunol. 2009;149 Suppl 1:102-7. doi: 10.1159/000211381. Epub 2009 Jun 3. Int Arch Allergy Immunol. 2009. PMID: 19494514 Review.
In addition to classical HES criteria, the World Health Organization proposed a set of criteria that distinguish chronic eosinophilic leukemia (CEL) from HES. As such, the fusion gene FIP1L1/PDGFRA was found as a cause of CEL in a significant proportion of pa …
In addition to classical HES criteria, the World Health Organization proposed a set of criteria that distinguish chronic eosinophi …
93 results